



ASX Announcement

13 April 2021

Avecho receives Ethics Approval for a Phase I Human Clinical Trial to Characterise Drug Absorption from its Enhanced Cannabidiol Product

Key highlights

- Avecho has received ethics approval to conduct an Australian Phase I PK study to characterise the absorption profile of cannabidiol (CBD) in healthy volunteers
- The Avecho CBD formulation is currently being manufactured as a pharmaceutical soft-gel product by Catalent Inc (CTLT, NYSE)
- The Company is already participating in the CA Clinics Observational Study (CACOS), Australia's largest running observational study of medicinal cannabis products in patients
- Increasing the absorption of cannabinoids will support the development of differentiated cannabinoid products on market, with greater therapeutic potential and/or reduced cost to patients
- Avecho has commenced detailed planning for its development program beyond Phase I, with a focus on TGA registration

Melbourne, Australia, 13 April 2021 - Avecho Biotechnology Limited (ASX:AVE, "Avecho", or "the Company") is pleased to advise that it has received ethics approval for its Phase I clinical trial, that will characterise the absorption profile of cannabidiol (CBD) from its TPM[®]-enhanced pharmaceutical CBD product in healthy volunteers.

Avecho's oral CBD formulation has already been demonstrated to increase the oral bioavailability of CBD in animal models when compared to standard CBD preparations. Increasing the absorption of cannabinoids will support the development of differentiated cannabinoid products on the market, with potential for greater therapeutic potential and/or reduced cost to patients. The Company is already participating in the CA Clinics Observational Study (CACOS), Australia's largest running observational study of medicinal cannabis products in patients, to gather real world feedback on how this product will perform for a range of indications that currently utilise medicinal cannabis therapy.

Today, Avecho announced another critical step forward in its CBD program, having received ethics approval to progress a Phase I human clinical trial to characterise CBD absorption from the enhanced CBD formulation.

Avecho CEO, Dr Paul Gavin, said: *"Avecho's oral CBD formulation is now being taken into formal Phase I clinical trials, which is the first step toward our primary goal of developing differentiated CBD products for pharmaceutical registration."*

The study will measure the safety and absorption profile of the CBD product developed with TPM[®] and the data will form an integral part of a future TGA submission and drug label. The study will take place at CMAX in Adelaide with 16 healthy volunteers. The study will be a cross-over design comparing the absorption of CBD after consumption of soft-gel capsules at two different doses; 75 mg and 150 mg. These clinical doses were chosen to align with the TGA's down-scheduling of CBD, which has specified that future over-the-counter CBD products must have a maximum daily dose of 150 mg

Catalent is currently supporting the development of the CBD soft-gel capsules at its St. Petersburg, Florida, facility in the U.S. based on Avecho's prototype formulation for use in the clinical trial. The 75 mg CBD dose per soft-gel capsule will support twice daily dosing for indications benefiting from prolonged drug delivery (such as anxiety), or for the consumption of two capsules together for indications requiring a higher, single dose (for indications such as insomnia). Catalent is a leading global provider of advanced drug delivery



technologies, development, and manufacturing solutions to help life science innovators develop and launch successful pharmaceuticals, cell and gene therapies, and consumer health products.

Avecho CEO, Dr Paul Gavin, said: *"We are focused on producing a high-quality product that meets regulatory requirements for a pharmaceutical product. Consequently, the chemistry, manufacturing and control requirements are extensive – and something we are carefully executing to ensure we are successful. The work being conducted by Catalent will aim to turn our prototype formulation into a pharmaceutical dosage form and will form a significant component of future regulatory dossier."*

Exact timelines for dosing in the Phase I clinical trial are subject to the evolving chemistry, manufacturing and controls (CMC) work at Catalent, but are anticipated to be early Q3. Avecho is now planning a larger development program beyond this Phase I study. This includes the clinical indication that will be targeted in a future pivotal clinical trial, as well as the regulatory, clinical, CMC and safety studies required to submit a dossier to the TGA for product registration.

Investor + General Enquiries

Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - avecho.com.au

Forward-Looking Statements

Certain statements in this announcement are forward looking statements. Forward looking statements can generally be identified by the use of words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "may", "assume" and words of similar import. These forward-looking statements speak only as at the date of this announcement. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by AVE that the forward-looking statements contained in this announcement are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, AVE and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this announcement or any error or omission therefrom.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, AVE disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of AVE since the date of the announcement.